Funder: METAvivor
Due Dates (Anticipated): March 2027 (Letter of Intent) | August 2027 (Invited full application)
Funding Amounts: Up to $450,000 over three years, with a $150,000 annual maximum
Summary: Supports translational and clinical research on established breast cancer metastases to improve outcomes for people living with stage IV disease.
Key Information: Applicants must hold an independent doctoral-level position at a U.S. academic, nonprofit, or governmental institution; all research must occur in the United States.
Description
METAvivor’s Translational Research Award supports established investigators addressing critical problems or barriers in metastatic breast cancer research. Projects must have clear potential to benefit people already living with metastasized or stage IV breast cancer. Discovery-based work may use well-established or validated models, molecules, pathways, biomarkers, or treatments.
Priority goes to research that could directly improve clinical outcomes or provide a conceptual foundation for better treatments, including mechanistic and preclinical animal studies. Relevant areas include treatment-response biomarkers, novel therapeutic targets, immunotherapy, animal or organoid models, tumor microenvironment research, and interventions addressing U.S. metastatic health disparities. Experienced patient advocates must contribute to application preparation and the funded project, ideally including someone living with metastatic breast cancer.
